Immupharma Share Discussion Threads

[ny boy] 08/1/2018 15:26

Where does it say 386p target?

[che7win] 08/1/2018 15:25

Alban, The 386p target is only for milestone payments, that would be on top of the 237p and 50p per share?

[jpleight] 08/1/2018 15:23

650k buys vs 299 sells. at the moment

[top tips] 08/1/2018 15:20

hottingup #8987, IMM's Annual Results stated the Phase 3 lupuzor trial involves 200 patients, split geographically as follows:

a) US: 11 sites, 70 patients.

b) Europe: 5 countries (Czech Republic, France, Germany, Hungary & Poland), 81 patients.

c) Mauritius: One site, 49 patients.

You could be right that those sites who finished some time ago will already have had all the data collected and it will be ready for unblinding the day after the trial ends next week. So IMM may start to get an idea of results quite soon. I believe they commenced dosing in the US, then Europe and lastly Mauritius was added and the number of planned European sites reduced, so they may already have data for the US and EU (which constitutes 151 [75.5%] of the 200 patients) ready for unblinding and analysis.

------

hottingup
8 Jan '18 - 13:09 - 8987 of 9032

I presume some territories finished the Phase 3 trial some time ago and all the data from them has already been collected by Simbac-Orion and could be unblinded the day after the last patient evaluation in the one outstanding territory next Wednesday.

Thus by the end of next week IMM could already have results for say the US and EU, and just be waiting for Mauritius, but would have a good idea of outcomes from the unblinded groups.

[albanyvillas] 08/1/2018 15:12

Fincapp 386p target BUY



Last patient completes dosing on Lupuzor
BUY
We note Immupharma’s (IMM) announcement this morning that the final patient has completed dosing in the Lupuzor pivotal phase III study with no reportable safety concerns. With all 200 patients having now successfully completed the global multi-centred trial, we await top-line results in Q1-18 (March 2018). Lupuzor aims to modulate the immune system in patients with Systemic Lupus erythematous (SLE), using a novel approach that offers significant benefits over the single existing approved SLE treatment on the market (Benlysta, GSK). We retain our Buy recommendation and 237p price target, having highlighted in our initiation (12 December 2017) the significant upside for IMM if phase III results are positive.
Special Protocol Assessment (SPA) tempers our approval estimate for Lupuzor to 63% with close FDA interaction both prior to and during Phase III pivotal trials. Simbec-Orion is an established, well regarded CRO with experience in conducting autoimmunity clinical trials.
Safety continues to be demonstrated, with no patients having elicited side effects or drug-related issues. This remains a key facet of Lupuzor’s business case in that it could offer increased efficacy and superior safety to Benlysta if launched (expected mid-2019).
237p price target and Buy recommendation reaffirmed which increases 87% on +ve Phase III results and also excludes the value of any potential upfront and milestone payments that could amount to 50p and 386p, respectively.



Fincapp 386p target BUY



Last patient completes dosing on Lupuzor
BUY
We note Immupharma’s (IMM) announcement this morning that the final patient has completed dosing in the Lupuzor pivotal phase III study with no reportable safety concerns. With all 200 patients having now successfully completed the global multi-centred trial, we await top-line results in Q1-18 (March 2018). Lupuzor aims to modulate the immune system in patients with Systemic Lupus erythematous (SLE), using a novel approach that offers significant benefits over the single existing approved SLE treatment on the market (Benlysta, GSK). We retain our Buy recommendation and 237p price target, having highlighted in our initiation (12 December 2017) the significant upside for IMM if phase III results are positive.
Special Protocol Assessment (SPA) tempers our approval estimate for Lupuzor to 63% with close FDA interaction both prior to and during Phase III pivotal trials. Simbec-Orion is an established, well regarded CRO with experience in conducting autoimmunity clinical trials.
Safety continues to be demonstrated, with no patients having elicited side effects or drug-related issues. This remains a key facet of Lupuzor’s business case in that it could offer increased efficacy and superior safety to Benlysta if launched (expected mid-2019).
237p price target and Buy recommendation reaffirmed which increases 87% on +ve Phase III results and also excludes the value of any potential upfront and milestone payments that could amount to 50p and 386p, respectively.



Fincapp 386p target BUY



Last patient completes dosing on Lupuzor
BUY
We note Immupharma’s (IMM) announcement this morning that the final patient has completed dosing in the Lupuzor pivotal phase III study with no reportable safety concerns. With all 200 patients having now successfully completed the global multi-centred trial, we await top-line results in Q1-18 (March 2018). Lupuzor aims to modulate the immune system in patients with Systemic Lupus erythematous (SLE), using a novel approach that offers significant benefits over the single existing approved SLE treatment on the market (Benlysta, GSK). We retain our Buy recommendation and 237p price target, having highlighted in our initiation (12 December 2017) the significant upside for IMM if phase III results are positive.
Special Protocol Assessment (SPA) tempers our approval estimate for Lupuzor to 63% with close FDA interaction both prior to and during Phase III pivotal trials. Simbec-Orion is an established, well regarded CRO with experience in conducting autoimmunity clinical trials.
Safety continues to be demonstrated, with no patients having elicited side effects or drug-related issues. This remains a key facet of Lupuzor’s business case in that it could offer increased efficacy and superior safety to Benlysta if launched (expected mid-2019).
237p price target and Buy recommendation reaffirmed which increases 87% on +ve Phase III results and also excludes the value of any potential upfront and milestone payments that could amount to 50p and 386p, respectively.

[aussieb3] 08/1/2018 15:11

Well put it this way if u listen to interview with Tim McCarthy , which was a few months ago they were getting everything in place of the manufacturing process. That's confidence for u and they probably would had halve of the results by then as many people would had finished the trials as people started at different dates .

[albanyvillas] 08/1/2018 15:03

Fincapp 386p target BUY


Last patient completes dosing on Lupuzor
BUY
We note Immupharma’s (IMM) announcement this morning that the final patient has completed dosing in the Lupuzor pivotal phase III study with no reportable safety concerns. With all 200 patients having now successfully completed the global multi-centred trial, we await top-line results in Q1-18 (March 2018). Lupuzor aims to modulate the immune system in patients with Systemic Lupus erythematous (SLE), using a novel approach that offers significant benefits over the single existing approved SLE treatment on the market (Benlysta, GSK). We retain our Buy recommendation and 237p price target, having highlighted in our initiation (12 December 2017) the significant upside for IMM if phase III results are positive.
Special Protocol Assessment (SPA) tempers our approval estimate for Lupuzor to 63% with close FDA interaction both prior to and during Phase III pivotal trials. Simbec-Orion is an established, well regarded CRO with experience in conducting autoimmunity clinical trials.
Safety continues to be demonstrated, with no patients having elicited side effects or drug-related issues. This remains a key facet of Lupuzor’s business case in that it could offer increased efficacy and superior safety to Benlysta if launched (expected mid-2019).
237p price target and Buy recommendation reaffirmed which increases 87% on +ve Phase III results and also excludes the value of any potential upfront and milestone payments that could amount to 50p and 386p, respectively.

[che7win] 08/1/2018 14:25

I've added today, expect these to be over 200p in the next few weeks.

[hjs] 08/1/2018 14:20

I would ignore the Panmure recommendation.

[runtoma] 08/1/2018 13:59

That is a dangerous game you are playing medical rep njb67

[che7win] 08/1/2018 13:58

Yep, 24th January last year, Panmure were dropped and Nortland remained only house broker.Panmure a bit bitter seeing they have had a 100p price target for the past year despite all the progress since.

[nw99] 08/1/2018 13:54

Do not expect to be queried

[john09] 08/1/2018 13:54

How did you cut and paste it earlier then. Give it a rest mate this is painful .

[che7win] 08/1/2018 13:53

Panmure, weren't they once the house brokers and IMM dumped them?They have had this target for over a year, I'd prefer to go with the independent valuation from Finncap.SCSW will also have talked to IMM most recently, they deemed it their nap this year.

[nw99] 08/1/2018 13:53

Because u did not believe me so I asked my broker to get it for you guys

[john09] 08/1/2018 13:52

Ps I’m glad you bought on the spike this morning then saw the sell rec lol

[john09] 08/1/2018 13:50

Oh so now you have the cut and paste ! And the link! But before it was an email

[nw99] 08/1/2018 13:48

Just shows you have no idea